Impact of COVID-19 on
Immunogenicity of Biologics
Friday, October 23, 2020
Impact of COVID-19 on Immunogenicity of Biologics (Part 2)
The schedule is in EST Time Zone. To check your local time, click here.
11:45 AM Speed Networking Session
Please come camera ready for effective speed networking! You will have a few minutes to interact with attendees in your room before being directed to another room. Be ready to drop your LinkedIn profile or your email address in the chatbox for further follow-up.
11:55 AM Organizer’s Opening Remarks
Emily Le, PhD, Founder & CEO, Bioinsider
12:00 PM Roundtable Discussion: Impact of COVID-19 on Immunogenicity of Biologics (Part 2)
Co-Moderator: Vibha Jawa, PhD, Executive Director, Non Clinical Disposition and Biotherapeutic Bioanalysis, Bristol-Myers Squibb
Co-Moderator: Narendra Chirmule, PhD, CEO, SymphonyTech Biologics; CSO, AcuImmune
- What is the influence of the inflammasome activation? What are the roles of the inflammasome in activation of IL-6, IL-18, and IL1b, and regulation of cytokine storm?
- What is the influence of the Th1/Th2/Th17 immune regulation?
- Can SARS-COV2 infection lead to enhanced risk for autoimmunity?
- What is the influence of COVID-19 on B cell responses?
1:00 PM End of Friday Roundtable
Meet Our Moderators
Narendra Chirmule, PhD, CEO, SymphonyTech Biologics; CSO, AcuImmune
Dr. Chirmule is currently the CEO at the SymphonyTech Biologics and also the CSO at the AcuImmune. With over 23 years of experience in Immunology, he has held senior leadership positions at Amgen and Merck, in the US, in the departments of Clinical Immunology overseeing drug development in regulated laboratories. He is an expert in the area of immune responses to biologics and vaccines. Narendra completed his post-doctoral training at Cornell University Medical College, New York, and has teaching and research experience as Assistant Director at the Human Gene Therapy Group of the University of Pennsylvania. He is an advisor to the Filovirus consortium and a reviewer on the HIV vaccine study section for the National Institutes of Health. He is also an academician conducting Biotech educational seminars and has published extensively (more than 100) on the topics of immunogenicity prediction and assessment, predictive toxicology, and quality-by-design. Narendra is an MS (Zoology, Animal Physiology) and Ph.D.in Applied Biology from the University of Mumbai
Vibha Jawa, PhD, Executive Director, Non Clinical Disposition and Biotherapeutic Bioanalysis, Bristol-Myers Squibb
Dr. Vibha Jawa obtained her Ph.D. in Biochemistry and Immunology with a thesis work studying the immune mechanisms behind autoimmune diseases. This was followed by a postdoctoral fellowship at the University of Pennsylvania where she did extensive work on assay development for monitoring the immune response to viral vectors. She then moved to the Bay area where she worked with a gene therapy company evaluating viral vectors for hemophilia therapy. Subsequently, she moved to Southern California where she worked for the City of Hope Cancer Centre Stem Cell and Gene Therapy group prior to moving to Amgen in 2003. Until recently she was a Principal Investigator and Clinical Immunology representative on several of Amgen’s drug development teams where she provided input to develop appropriate immunogenicity risk assessment strategies. Her current research interests include evaluating immune response biomarkers for early drug development and efficacy, immunogenicity prediction using in silico, in Vitor, and in vivo technologies, modeling the impact of immunogenicity on PK and PD, antigen processing and presentation and the role of T cells in the immune response to drug products.